2025 Conditions Extraction Treatment 
Cannabis Law Report
JUNE 28, 2021
Pharmaceutical and Medical Cannabis Leaders Zambon GmbH and Adven GmbH will Drive Medical Cannabis Supporting Treatments for Neurological Therapies. The aim of the agreement is to make medical cannabis treatments available to patients, with an initial focus on neurological therapies. billion 1 by 2025.
Cannabis Law Report
DECEMBER 23, 2021
billion by 2025. However, no single cannabinoid drug has received widespread approval in the treatment of pain. The market sizing section provides forecasts on the estimated sales of the three most lucrative cannabinoid pharmaceuticals – from 2021-2025 – including Epidiolex, Sativex and Dronabinol.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
JULY 26, 2022
The health minster pointed out that his ministry had done an intensive study of the drug for three years, after which they had become convinced of its efficacy in the treatment of many diseases, including cancer, Parkinson’s and mental disorders. According to the Thai health minister, only a 0.2 But the economic impact is huge,” he said.
Cannabis Law Report
JANUARY 12, 2020
It has approved use of cannabis extracts for treatment of a range of illnesses and conditions, including cancer, epilepsy, Alzheimer’s, Parkinson’s disease and anxiety. billion ($96 billion) by the end of 2025. Read more at [link].
Cannabis Law Report
JULY 8, 2021
Despite the fact that cannabis also isn’t approved for use by the Food & Drug Administration, advocacy organizations claim that smoking cannabis is a viable treatment for a number of behavioral and health issues, ranging from tension and worry to Frontotemporal disease and Parkinson’s disease (FDA).
Cannabis Law Report
FEBRUARY 18, 2020
Researchers predict that the market will be valued at $7 billion by the year 2025. And according to a Nielsen analytical report , the US market of legal marijuana will reach $41 billion in revenue by 2025, meaning that New York will make up close to 17% of the market share. In 2018, the New York legal cannabis market reached $1.8
Cannabis Law Report
MAY 19, 2019
Cannabis plant or its resin or extract with THC content lower than 1% is considered as CBD (medical) cannabis and not psychoactive. billion dollars by 2025. Some conditions like lung cancer and Emphysema have been shown to regress when cannabis is thrown to the mix. Economic benefits of Marijuana: Thailand as a Case Study.
Expert insights. Personalized for you.
105 
Let's personalize your content